Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care
Introduction: Dalbavancin is an antibiotic administered by intravenous infusion weekly or bi-weekly and is currently FDA-approved only for treatment of skin and soft-tissue infections. It has shown promise, but is not considered the standard of care, for bacteremia and infective endocarditis (IE), w...
Main Authors: | Leama Ajaka, Emily Heil, Sarah Schmalzle |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/9/10/700 |
Similar Items
-
Long term surgical outcomes for infective endocarditis in people who inject drugs: a systematic review and meta-analysis
by: David Goodman-Meza, et al.
Published: (2019-11-01) -
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
by: Carmen Hidalgo-Tenorio, et al.
Published: (2019-10-01) -
Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections
by: Jacqueline T. Bork, et al.
Published: (2019-05-01) -
Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study
by: Lucas Wiessing, et al.
Published: (2017-04-01) -
Patients with infective endocarditis and history of injection drug use in a Swedish referral hospital during 10 years
by: Anna Damlin, et al.
Published: (2021-03-01)